New Delhi, Jan 14 || New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report.
The report by GlobalData, a data and analytics company, showed that the growth will particularly be visible in eight major markets -- US, France, Germany, Italy, Spain, UK, Japan, and China.
The report forecasted that the Alzheimer’s disease market in these countries to grow from $2.4 billion in 2023 to $19.3 billion by 2033 at a compound annual growth rate (CAGR) of 23.4 per cent.
This will be primarily driven by the entry of expensive disease-modifying therapies (DMTs) into the market, which will likely result in increased treatment rates as more options become available. An ageing global population leading to an increase in prevalent cases, and the launch of novel symptomatic therapies for the treatment of agitation and psychosis associated with Alzheimer’s disease will also contribute to the growth.
By 2033, DMTs are expected to dominate the global Alzheimer’s disease market, contributing 73.5 per cent of the market, with drugs targeting amyloid beta making up the majority of this, the report said.